| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2006.09.7535 |
| P698 | PubMed publication ID | 17606972 |
| P50 | author | Linda T Vahdat | Q40149511 |
| P2093 | author name string | Francesco Cognetti | |
| Jean-Pierre Delord | |||
| Pierre Kerbrat | |||
| David Lebwohl | |||
| Henri Roché | |||
| Hervé Curé | |||
| Louise Yelle | |||
| Craig Bunnell | |||
| Louis Mauriac | |||
| Ronald Peck | |||
| Joseph Sparano | |||
| Rana Ezzeddine | |||
| P433 | issue | 23 | |
| P921 | main subject | phase II clinical trial | Q42824440 |
| ixabepilone | Q11711607 | ||
| metastatic breast cancer | Q12859063 | ||
| P304 | page(s) | 3415-3420 | |
| P577 | publication date | 2007-07-02 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy | |
| P478 | volume | 25 |
| Q43152531 | A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma |
| Q37172818 | A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases |
| Q33526311 | A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma |
| Q33387547 | A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial |
| Q36892821 | A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. |
| Q35975007 | Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone |
| Q35872691 | Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy |
| Q89623255 | An Easy and Efficient Strategy for the Enhancement of Epothilone Production Mediated by TALE-TF and CRISPR/dcas9 Systems in Sorangium cellulosum |
| Q33999018 | Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. |
| Q26865369 | Beyond taxanes: the next generation of microtubule-targeting agents |
| Q24633167 | Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer |
| Q36245461 | Current approaches to the management of Her2-negative metastatic breast cancer |
| Q90554778 | Differential Morphological and Biochemical Recovery from Chemotherapy-Induced Peripheral Neuropathy Following Paclitaxel, Ixabepilone, or Eribulin Treatment in Mouse Sciatic Nerves |
| Q55407807 | Effects of transcriptional mode on promoter substitution and tandem engineering for the production of epothilones in Myxococcus xanthus. |
| Q35599745 | Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer |
| Q37067999 | Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. |
| Q38555471 | Glucocorticoids and Cancer. |
| Q34611801 | Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer. |
| Q37797749 | Ixabepilone Plus Capecitabine for Breast Cancer Patients With an Early Metastatic Relapse After Adjuvant Chemotherapy: Two Clinical Trials |
| Q28534786 | Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial |
| Q37356274 | Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer |
| Q34788890 | Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer |
| Q34417996 | Ixabepilone development across the breast cancer continuum: a paradigm shift |
| Q46173239 | Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium |
| Q34180965 | Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials |
| Q34562783 | Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients |
| Q37290709 | Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer |
| Q34418413 | Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer |
| Q28298312 | Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer |
| Q37563451 | Ixabepilone: in locally advanced or metastatic breast cancer |
| Q34289839 | Kinesins and cancer. |
| Q36714374 | Locoregional interaction of ixabepilone (ixempra) after breast cancer radiation |
| Q37403186 | Management of advanced breast cancer with the epothilone B analog, ixabepilone |
| Q37996079 | Medical therapy of endometrial cancer: current status and promising novel treatments. |
| Q30448951 | Neurological adverse effects caused by cytotoxic and targeted therapies. |
| Q37057994 | New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones. |
| Q37307168 | Novel combinations for the treatment of metastatic breast cancer |
| Q28279384 | Novel cytotoxic agents: epothilones |
| Q34611212 | Novel microtubule-targeting agents - the epothilones. |
| Q37321909 | Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone |
| Q34636002 | Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm |
| Q34204598 | Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer |
| Q37730282 | Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma |
| Q37104791 | Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors |
| Q36988082 | Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors |
| Q30433670 | Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study |
| Q34915389 | Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group |
| Q34274925 | Present and future evolution of advanced breast cancer therapy |
| Q35847455 | Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NC |
| Q33990883 | Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane |
| Q36273796 | Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products |
| Q35076330 | Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence |
| Q37791482 | The microtubule as a breast cancer target |
| Q36057858 | Treatment of Breast Cancer Brain Metastases |
| Q37707615 | Treatment options for advanced endometrial carcinoma |
| Q37207961 | Treatment options for breast cancer resistant to anthracycline and taxane |
| Q37350227 | Update on medication-induced peripheral neuropathy |
Search more.